|Bid||45.78 x 4000|
|Ask||0.00 x 1800|
|Day's range||44.59 - 45.84|
|52-week range||33.53 - 46.86|
|Beta (5Y monthly)||0.38|
|PE ratio (TTM)||19.85|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||2.20 (4.98%)|
|Ex-dividend date||18 Nov 2021|
|1y target est||48.38|
Gilead (GILD) efforts to build an oncology franchise get jolted as the FDA places hold on a few studies evaluating the combination of magrolimab plus azacitidine.
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2022, which should boost the top line in the long term.
Following positive data from phase II study, SAB Biotherapeutics (SABS) starts a phase III study evaluating its COVID antibody treatment.